Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp105 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2013

α2C AR KO mice present opposite bone phenotype in femur and vertebrae

Teixeira Marilia Bianca , Martins Gisele , Costa Cristiane , Brum Patricia , Gouveia Cecilia

α2C Evidences demonstrate that sympathetic nervous system (SNS) activation causes osteopenia via β2-adrenoceptor (β2-AR) signaling. In a recent study, we showed that female mice with chronic sympathetic hyperactivity due to double knockout of adrenoceptors that negatively regulate norepinephrine release, α2A-AR and α2C-AR (α2A/α2C-ARKO), present an unexpected phenoty...

ba0001pp157 | Cancer and bone: basic, translational and clinical | ECTS2013

Bone metastatic prostate cancer cells regulate their growth via impairing osteoblast differentiation

van Driel Marjolein , Robbesom Iris , Koster Ruben , Boers-Sijmons Bianca , Chiba Hideki , van Leeuwen Hans

Metastases to the bone are the incurable final outcomes of cancer, reducing both length and quality of life in an aggressive way. Despite the discoveries of many factors involved, no cure has been found. Metastatic outgrow starts in interaction with the bone micro-environment. The first attachment in bone is with the osteoblasts lining the endosteal surface. Our aim is to study the role of the osteoblasts in metastatic tumor spread and growth.We used an ...

ba0005p471 | Paediatric bone disease | ECTS2016

Bone involvement and intervertebral disc calcifications in beta-thalassemic patients: a retrospective study

de Sire Alessandro , Moretti Antimo , Bianco Massimiliano , Gimigliano Francesca , Iolascon Giovanni

Background: Bone involvement in patients with β-thalassemia is well known, but only few studies have analyzed bone microarchitecture and the prevalence of intervertebral disc calcifications (IDCs) in these patients. The aim of our study was to evaluate the bone quality in a group of patients with β-thalassemia in terms of geometry and microarchitecture properties; moreover, we evaluated the presence of IDCs in these patients.Material and method...

ba0002oc21 | Miscellaneous | ICCBH2013

A randomized, double-blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone

Boyce Alison M , Kelly Marilyn H , Brillante Beth A , Kushner Harvey , Wientroub Shlomo , Riminucci Mara , Bianco Paolo , Robey Pamela G , Collins Michael T

Fibrous dysplasia (FD) is a benign skeletal disease caused by activating mutations of Gsα. These mutations lead to formation of abnormal and mechanically unsound bone and fibrotic tissue. Clinical sequelae include deformity, fracture, and pain. Studies in bisphosphonates have shown improvement in bone pain and inconsistent effects on FD mineralization; however interpretation has been limited by a lack of controlled trials.Objecti...